Chromone-lipoic acid conjugate: Neuroprotective agent having acceptable butyrylcholinesterase inhibition, antioxidant and copper-chelation activities

Jalili-Baleh L., Nadri H., Forootanfar H., Kucukkilinc T. T., AYAZGÖK B., Sharifzadeh M., ...More

DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, vol.29, no.1, pp.23-38, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1007/s40199-020-00378-1
  • Journal Name: DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.23-38
  • Keywords: Alzheimer's disease, Lipoic acid, Chromone, Multifunctional agent, Antioxidant, TARGET-DIRECTED LIGANDS, ALZHEIMERS-DISEASE, DRUG DISCOVERY, HYBRIDS, DESIGN, ACETYLCHOLINESTERASE, RIVASTIGMINE, CHEMISTRY, THERAPY, POWER
  • Hacettepe University Affiliated: Yes

Abstract

Purpose Alzheimer's disease (AD) is a multifaceted neurodegenerative disease. To target simultaneously multiple pathological processes involved in AD, natural-origin compounds with unique characteristics are promising scaffolds to develop novel multi-target compounds in the treatment of different neurodegenerative disease, especially AD. In this study, novel chromone-lipoic acid hybrids were prepared to find a new multifunctional lead structure for the treatment of AD.